Oncology "big-wig" for sure ...
Daniel D. Von Hoff is the physician in chief and director of translational research at Translational Genomics Research Institute (TGen), and current Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute. He is also a professor of medicine at the Mayo Clinic and medical director of research as well as chief scientific officer at US Oncology. He is most notable for his work in targeted therapies for the treatment of cancer.[1] He led the development of gemcitabine,[2] and has several drugs in development.
Ann: Distinguished Oncologist Daniel Von Hoff Joins as Consultant, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.010(0.86%) |
Mkt cap ! $204.1M | |||
| Open | High | Low | Value | Volume |
| $1.19 | $1.19 | $1.17 | $19.63K | 16.71K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 810 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 2188 | 1 |
View Market Depth
| Last trade - 15.52pm 11/07/2025 (20 minute delay) ? |
| RAC (ASX) Chart |